A diverse set of issues characterize the Life Sciences sector, due to the breadth of industries served in this practice area. In agribusiness, companies face continual challenges to develop product treatments that provide better performance and are more environmentally friendly – particularly to aid the rapidly growing organic produce business. Great market opportunities exist for companies seeking to participate in the emerging biofuels market and the leading agribusiness firms are certainly eager to lead the development of this market.
In pharmaceuticals, the issues are driven by the state of world health care, from the emergence and treatment of new and existing diseases, to the ability of local economies to adequately provide services and cover health care costs. The cost, time, and potential liability to commercialize a new drug are always increasing, forcing pharmaceutical companies to scrutinize all development efforts and third-party alliances.
Our project work covers evaluating new opportunities in many forms, from evaluating a new technology that can be used to deliver a pesticide for the consumer market to assessing the potential to commercialize a new indication in pharmaceuticals. Building on decades of experience in tracking this and the global Rx-to-OTC arena, we
undertake many projects to assess opportunities in the OTC area. We can help our clients determine if an early-stage technology is worth the investment, or help them determine the sales and profits to expect from a Rx-to-OTC switch of a particular drug.
|
